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Background: Cachexia in both mice and humans is associated with tumour production of a sulphated glycoprotein called
proteolysis-inducing factor (PIF). In mice PIF binds with high affinity to a surface receptor in skeletal muscle, but little is known
about the human receptor. This study compares the human PIF receptor with the murine.
Methods: Human PIF was isolated from the G361 melanoma and murine PIF from the MAC16 colon adenocarcinoma. The human
PIF receptor was isolated from human skeletal muscle myotubes. Protein synthesis and degradation induced by human and
murine PIF was studied in human and murine skeletal muscle myotubes.
Results: Both the human and murine PIF receptors showed the same immunoreactivity and Mr 40 000. Both murine and human PIF
inhibited total protein synthesis and stimulated protein degradation in human and murine myotubes to about the same extent,
and this was attenuated by a rabbit polyclonal antibody to the murine PIF receptor, but not by a non-specific rabbit antibody. Both
murine and human PIF increased the activity of the ubiquitin–proteasome pathway in both human and murine myotubes, as
evidenced by an increased ‘chymotrypsin-like’ enzyme activity, protein expression of the 20S and 19S proteasome subunits, and
increased expression of the ubiquitin ligases MuRF1 and MAFbx, and this was also attenuated by the anti-mouse PIF receptor
antibody.
Conclusions: These results suggest that the murine and human PIF receptors are identical.
Patients with cancer frequently experience cachexia, a wasting
syndrome characterised by massive losses of both muscle and fat. In
lung cancer patients muscle mass decreased by 75%, and total body
fat by 85% when they had lost 32% of their pre-illness stable weight
(Fearon, 1992). Muscle atrophy causes weakness, reducing the ability
of the patient to carry out normal activities, while death occurs when
the weight loss reaches 25%–30% (Wigmore et al, 1997).
We have shown that both murine and human tumours, which
induce muscle atrophy elaborate a catabolic glycoprotein called
proteolysis-inducing factor (PIF; Todorov et al, 1996). Proteolysis-
inducing factor expression was associated with an increased rate of
weight loss in patients with a tumour of the head of the pancreas
(Wigmore et al, 2000), and in patients with non-small-cell lung
cancer (NSCLC; Wang et al, 2010). In patients with NSCLC PIF
expression was negatively related to the survival of the patients
(Wang et al, 2010). Proteolysis-inducing factor contains one
O-linked and one N-linked sulphated oligosaccharide chain
(Todorov et al, 1997), which would facilitate its high affinity
binding to a surface receptor of Mr 40 000 in skeletal muscle
(Todorov et al, 2007). Antiserum to the N-terminal 19 amino acids
of the PIF receptor (PIFR) attenuated protein degradation initiated
by PIF in vitro, as well as loss of skeletal muscle and body weight in
mice bearing the cachexia-inducing MAC16 tumour (Todorov
et al, 2007). The N-terminal peptide also attenuated protein
degradation induced by PIF in vitro (Mirza et al, 2011). These
results suggest that the receptor is linked to the signalling system
that initiates protein degradation in response to PIF.
Since the PIFR may play a central role in the initiation of muscle
atrophy in cancer cachexia it could act as a potential target for
agents having a therapeutic role in this condition, particularly since
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antibodies to the PIFR attenuated muscle wasting in a pre-clinical
model of cachexia (Todorov et al, 2007). The aim of this study was
to determine if the human PIFR was similar to the mouse in terms
of immunoreactivity of the N-terminal sequence, to find out if the
mouse is a suitable model for pre-clinical testing of PIFR
antagonists. The potential application of antibodies to the PIFR
for the treatment of cancer cachexia has been previously published
(Tisdale et al, 2008).
MATERIALS AND METHODS
Materials. Dulbecco’s modified Eagle’s medium (DMEM),
McCoys 5a medium and horse serum (HS) were purchased from
PAA Laboratories (Somerset, UK), and fetal bovine (FBS) from
Biosera (East Sussex, UK). L-[2,3,4,5,6-3H] Phenylalanine
(sp.act.4.669 TBqmmol 1) was from Perkin Elmer Ltd
(Cambridge, UK). The chymotrypsin substrate (N-Succinyl-Leu-
Leu-Val-Tyr-7-amido-4-methylcoumarin) was obtained from
Sigma (Dorset, UK). The human melanoma cell line, G361 was
from the European Collection of Cell Cultures (Wilts, UK), and the
human skeletal muscle myoblasts together with their growth and
differentiation medium were from Zen-Bio, Inc. (Durham, NC,
USA). Mouse monoclonal antibodies to 20S proteasome a-subunits
and p42 were from Affinite Research Products (Exeter, UK), while
goat polyclonal antibody to MuRF1 and rabbit polyclonal antibody
to MAFbx and b-actin were from Santa Cruz Biotechnology
(Heidelberg, Germany). Peroxidase-conjugated donkey antirabbit
and sheep anti-mouse antibodies were purchased from GE
Healthcare (Bucks, UK) as was the enhanced chemiluminescence
(ECL) development hits. Peroxidase-conjugated donkey antigoat
antibody was from Abcam (Cambridge, UK), and nitrocellulose
membranes were from VWR (Bucks, UK). Polyclonal antisera to
the first 19 amino acids of the N-terminal sequence of the murine
PIFR (mPIFR; Todorov et al, 2007) was generated in rabbits by
Severn Biotech (Worcester, UK).
Cell culture. Human skeletal muscle myoblasts were maintained
in growth medium under an atmosphere of 10% CO2 in air at
371C. When 80% confluency was achieved they were transferred to
differentiation medium, with medium changes every 2 days.
Differentiation was complete in 6 days. The conditions for C2C12
murine myoblasts were similar except that cells were maintained in
DMEM supplemented with 10% FBS and glutamine, under an
atmosphere of 10% CO2 in air at 371C, and differentiation was
achieved in DMEM containing 2% HS in 3–5 days.
G361 cells were maintained in McCoys 5a medium supple-
mented with 10% FBS in a humidified atmosphere of 10% CO2 in
air at 371C. All experiments were performed on cells in the
subconfluent state.
Purification of PIF. Murine PIF was isolated from solid MAC16
tumours excised from mice with established weight loss as
previously described in detail (Mirza et al, 2011). Since PIF has
been shown to be resistant to pronase (Todorov et al, 1996) the
bulk protein was reduced by pronase digestion and the PIF was
isolated by adhesion to DEAE cellulose and elution with 0.3 M
NaCl. Human PIF was isolated from G361 cells by a similar
methodology as previously reported (Todorov et al, 1999), except
that ammonium sulphate precipitation was replaced by pronase
digestion.
Isolation of PIFR. Human and mouse PIFR was isolated from
human skeletal muscle myoblasts and C2C12 myoblasts as
previously reported (Todorov et al, 2007). The PIFR was purified
by wheat germ agglutinin (WGA) agarose affinity chromatography
after addition of PIF, based on the observation (Todorov et al,
1996) that this lectin will bind the oligosaccharide chain of PIF.
Measurement of 20S proteasome activity. The functional activity
of the 20S proteasome was determined as the ‘chymotrypsin-like’
enzyme activity as previously described (Whitehouse and Tisdale,
2003). Activity was measured by the release of aminomethyl
coumarin from a fluorogenic peptide in the absence and
presence of the specific proteasome inhibitor lactacystin (10 mM).
Only the activity suppressed by lactacystin was considered to be
proteasome specific.
Western blotting. Myotubes were scraped from the substratum
and washed with PBS prior to sonication at 41C in 20mM Tris-HCl
(pH 7.4), 2mM ATP, 5mM MgCl2 and 1mM DTT. Cytosolic
protein (5 mg) formed by centrifugation at 18 000 g for 10min at
41C was resolved on 12% SDS–PAGE at 180V for 1 h, followed by
transference onto 0.45 mm nitrocellulose membranes at 300mA for
1 h. The membranes were blocked with 5% Marvel in Tris-buffered
saline (pH 7.5) for 1 h at room temperature. The primary
antibodies to the 20S proteasome and p42 were used at a dilution
of 1 : 1000, while those for MuRF1 and MAFbx were used at a
dilution of 1 : 200. The secondary antibodies were used at a dilution
of 1 : 5000. Incubation with the primary antibodies was overnight
at room temperature, while for the secondary antibodies it was 1 h
also at room temperature. Development was by ECL. Blots were
scanned by a densitometer to quantify differences.
Measurement of protein synthesis. Myotubes were formed in six-
well multiwell dishes, and were supplemented with DMEM
without HS for 18 h before experimentation. Proteolysis-inducing
factor-receptor antibody and non-specific rabbit IgG were added to
the cultures 2 h before adding PIF. Protein synthesis was carried
out after 4 h incubation with PIF. Cultures were supplemented with
2 ml (370 kBq) L-[2,3,4,5,6-3H] phenylalanine in 8ml sterile PBS,
and the plates were incubated for 4 h at 371C under an atmosphere
of 10% CO2 in air. Protein synthesis was linear over a 4-h period.
The reaction was arrested by washing three times with 1ml ice-
cold sterile PBS. Following removal of PBS, 1ml ice-cold 0.2 M
perchloric acid was added, and the plates were kept at 41C for
20min. The perchloric acid was substituted with 1ml of 0.3 M
NaOH/well, and incubation was continued for 30min at 41C,
followed by a further incubation at 371C for 20min. The NaOH
extract was removed and combined with a further 1-ml wash of
each well, and 0.5ml of 0.2 M perchloric acid was added and left on
ice for 20min. The extract was then centrifuged at 700 g for 5min
at 41C. The protein-containing pellet was dissolved in 1ml of 0.3 M
NaOH, and 0.5ml of the solution was counted for radioactivity
after mixing with 8ml Ultima Gold XR scintillation fluid.
Measurement of total protein degradation in myotubes. This
has previously been described in detail (Whitehouse and Tisdale,
2003). Myotubes were differentiated in six-well multiwell plates
and labelled for 24 h with L-[2,3,4, 5,6  3H] phenylalanine (2 mCi)
at 371C. Then the plates were washed extensively with PBS and
incubated for 2 h in fresh medium to allow degradation of short-
lived proteins. Protein degradation was determined by incubation
for a further 24 h in DMEM free of phenol red, but supplemented
with 2% HS, and in the presence of 2mM phenylalanine to prevent
reincorporation of the radioactivity in the absence or presence of
PIF (4.2 nM). Some myotubes were also treated with anti-receptor
or non-specific antibody (5 mgml 1) for 2 h prior to PIF addition.
The radioactivity released was expressed as a fraction of the total
incorporated into the myotubes.
Statistical analysis. Results are expressed as mean values±s.e. for
at least three replicate experiments. The significance of differences
in mean values between groups was determined by one-way
ANOVA followed by Tukey–Kramer multiple comparison test. P
values o0.05 were considered significant.
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RESULTS
The human PIFR (hPIFR) was isolated from human skeletal
muscle myotubes, produced by differentiation of skeletal muscle
myoblasts in vitro, using a WGA affinity column, as previously
described for the mPIFR; Todorov et al, 2007). Western blotting
showed that the hPIFR showed immunoreactivity to the rabbit
polyclonal antibody raised against the mPIFR (Figure 1), and that
both the hPIFR and the mPIFR had the same Mr 40 000 on SDS–
PAGE. We have previously reported that in skeletal muscle PIF
inhibits protein synthesis, as well as stimulating protein degrada-
tion, both in vitro (Eley and Tisdale, 2007) and in vivo (Lorite et al,
1997). In this study human PIF, isolated from the G361 human
melanoma (Todorov et al, 1999) and murine PIF isolated from the
MAC16 colon adenocarcinoma (Todorov et al, 1997), when used at
the optimum concentration (4.2 nM), previously observed (Eley and
Tisdale, 2007; Whitehouse and Tisdale, 2003), both significantly
inhibited protein synthesis in murine C2C12 myotubes (Figure 2A
and B), and in both cases this was attenuated by a rabbit polyclonal
antibody to the mPIFR, but not by a non-specific rabbit polyclonal
antibody. A previous study (Todorov et al, 2007) established that a
concentration of 5 mgml 1 of antibody gave optimal results. A
similar situation was observed in human myotubes (Figure 2C and D)
with both murine and human PIF inhibiting protein synthesis,
which was attenuated by the anti-mPIFR antibody, but not by a
non-specific polyclonal antibody.
In murine myotubes both human and murine PIF also
significantly stimulated total protein degradation, as determined
by the release of [3H] phenylalanine from pre-labelled cells
(Figure 3A and B), and in both cases this was attenuated by a
polyclonal antibody to the mPIFR, but not by a non-specific
polyclonal antibody. The extent of protein degradation by human
and murine PIF was approximately the same. In human myotubes
both murine and human PIF also initiated an increase in total
protein degradation (Figure 3C and D), to about the same extent.
Again the protein degradation induced by both human and murine
PIF was completely attenuated by the rabbit polyclonal antibody to
the mPIFR, but not by a non-specific rabbit polyclonal antibody
(Figure 3C and D).
The predominant catabolic pathway for protein degradation in
skeletal muscle is the ubiquitin–proteasome pathway (Lecker et al,
1999). The functional activity of the proteasome can be measured
as the ‘chymotrypsin-like’ enzyme activity, which is located on the
b-5 subunit of the 20S proteasome. As with total protein
degradation the proteasome ‘chymotrypsin-like’ enzyme activity
was increased by both murine and human PIF in murine
myotubes, and attenuated by the polyclonal antisera to the mPIFR
(Figure 4A and B). Both murine and human PIF also increased the
‘chymotrypsin-like’ enzyme activity of human muscle to about the
same extent (Figure 4C and D), and in both cases this was
attenuated by the rabbit anti-mPIFR antibody.
Western blotting of components of the ubiquitin–proteasome
pathway showed human PIF to increase expression of the 20S and
19S proteasome subunits in murine myotubes (Figure 5A and B), as
well as the ubiquitin ligases MuRF1 (Figure 5C) and MAFbx
(Figure 5D) and this was attenuated by the anti-murine PIF antibody.
Similarly in human myotubes murine PIF increased expression of the
20S and 19S proteasome subunits (Figure 6A and B), MuRF1
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Figure 2. Effect of anti-PIF-receptor antibody on the PIF-induced depression of protein synthesis in murine myotubes (A) and (B) and human
myotubes (C) and (D). Protein synthesis in C2C12 myotubes after 4 h incubation with either murine (A) or human (B) PIF (4.2 nM) and protein
synthesis in human myotubes after murine (C) or human (D) PIF (4.2 nM) in the absence or presence of rabbit anti-mPIFR antibody (rAb; 5mgml 1)
or non-specific rabbit antibody (nsAb; 5 mgml 1). Both antibodies were added 2h prior to PIF. The experiment was repeated three times.
Differences from control are indicated as a, Po0.05, while differences in the presence of antibody are shown as d, Po0.05.
1
40 kDa
2
Figure 1. Western blot of murine (lane 1) and human (lane 2) PIF
receptors on 12% SDS–PAGE using rabbit polyclonal antiserum to the
murine PIF receptor. The PIF receptors were purified as detailed in
methods.
Identity of PIF receptors on human and murine skeletal muscle BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2014.379 905
(Figure 6C) and MAFbx (Figure 6D), and this was also attenuated
by the anti-murine PIF antibody. These results suggest that the
murine and human PIFR are essentially identical.
DISCUSSION
Both human and murine PIF are identical with regard to the
central polypeptide chain (dermcidin; Lowrie et al, 2006), and
their oligosaccharide chains and sulphate modifications (Todorov
et al, 1997; Todorov et al, 1999). This study shows that the
receptors for PIF on human and murine skeletal muscles are also
identical in their molecular weights, immunoreactivity, respon-
siveness to depression in protein synthesis and increase in protein
degradation by human and murine PIF, and in their ability to
increase the expression of the major components of the
ubiquitin–proteasome pathway. The full sequence of neither the
human or murine PIFR is known, nor the PIF-binding site,
although it is likely to be a region of basic amino acids, since PIF
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Figure 3. Effect of anti-PIF-receptor antibody on PIF-induced protein degradation in murine myotubes (A) and (B) and human myotubes (C) and
(D). Total protein degradation in C2C12 myotubes after 24 h incubation with either murine (A) or human (B) PIF (4.2 nM) and in human myotubes
incubated with either murine (C) or human (D) PIF (4.2 nM) in the absence or presence of rabbit anti-murine PIFR antibody (rAb; 5 mgml 1), or non-
specific rabbit antibody (nsAb; 5mgml 1). Both antibodies were added 2h prior to PIF. The experiment was repeated three times. Differences
from control are indicated as b, Po0.01 or c, Po0.001, while differences in the presence of antibody are shown as e, Po0.01 or f, Po0.001.
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Figure 4. Proteasome ‘chymotrypsin-like’ enzyme activity in C2C12 myotubes after treatment with either murine (A) or human (B) PIF (4.2 nM) and
in human myotubes in the presence of murine (C) and human (D) PIF (4.2 nM) for 24 h in the absence, or presence of the anti-mPIFR antibody
(rAb; 5 mgml 1) added 2h prior to the PIF. The experiment was repeated three times. Differences from control are indicated as b, Po0.01 or c,
Po0.001, while differences in the presence of the anti-mPIFR antibody are shown as d, Po0.05, e, Po0.01 or f, Po0.001.
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is highly negatively charged (Todorov et al, 1997). The PIFR
belongs to a class of structurally conserved protein called DING
proteins, which are spread through the animal and plant
kingdom, and are highly conserved, particularly in the N-term-
inal 25–30 amino acids (Berna et al, 2002). Most eukaryotic
DING proteins have been identified in extracellular, or cell-
surface localisations, and show some structural homology with
phosphate-binding proteins (Berna et al, 2002), which might
explain the ability to bind PIF.
Binding of PIF to its receptor releases Ca2þ from the
endoplasmic reticulum in a Zn2þ -dependent process, and N-term-
inal peptides of the PIFR attenuated the rapid rise in intracellular
Ca2þ in skeletal muscle in response to PIF (Mirza and Tisdale,
2012). The rise in Ca2þ initiates a signalling cascade leading to a
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Figure 5. Western blots showing expression of the proteasome 20S a-subunit (A), 19S subunit (B), MuRF1 (C) and MAFbx (D) in C2C12 myotubes
after treatment with human PIF (4.2 nM) for 24 h in the absence or presence of anti-mPIFR antibody (5 mgml1) added 2h prior to PIF. Actin was
used as a loading control. The densitometric analysis is based on three separate western blots. Differences from control are indicated as a, Po0.05
or b, Po0.01, while differences in the presence of the anti-mPIFR antibody are indicated as d, Po0.05.
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Figure 6. Western blots showing expression of the proteasome 20S a-subunit (A), 19S subunit (B), MuRF1 (C) and MAFbx (D) in human myotubes
after treatment with murine PIF (4.2 nM) for 24 h in the absence or presence of the anti-mPIFR antibody (5 mgml1) added 2h prior to the PIF.
Actin was used as loading control. The densitometric analysis is based on three separate western blots. Differences from control are indicated as a,
Po0.05 or b, Po0.01, while differences in the presence of the anti-mPIFR antibody are shown as d, Po0.05.
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depression in protein synthesis and an increase in protein
degradation. This involves activation of both caspases-3 and -8,
which leads to activation of the dsRNA-dependent protein kinase
(PKR; Eley et al, 2010). Activation of PKR leads to a depression of
global protein synthesis through increased phosphorylation of
eukaryotic initiation factor 2 on the a-subunit (eIF2a), and increased
protein degradation through the ubiquitin–proteasome proteolytic
pathway through activation of the transcription factor nuclear
factor-kB (NF-kB; Eley and Tisdale, 2007).
Since both the N-terminal peptide of the PIFR and anti-PIFR
antibody attenuated protein degradation in vitro and loss of
skeletal muscle and body weight in vivo in a murine model of
cachexia the PIFR may be an appropriate target for the
development of agents to counteract muscle wasting in cancer,
and that the mouse may be an appropriate model for identifying
agents likely to be effective in humans.
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